{
    "2021-12-09": [
        [
            {
                "time": "",
                "original_text": "万泰生物现2笔大宗交易，共成交52,499.96万元",
                "features": {
                    "keywords": [
                        "万泰生物",
                        "大宗交易",
                        "成交额"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "万泰生物今日大宗交易成交22万股，成交价226.18元折价7.49%",
                "features": {
                    "keywords": [
                        "万泰生物",
                        "大宗交易",
                        "成交价",
                        "折价"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "万泰生物：公司拟在南非、印度尼西亚、菲律宾等11个国家进行鼻喷疫苗临床试验",
                "features": {
                    "keywords": [
                        "万泰生物",
                        "鼻喷疫苗",
                        "临床试验",
                        "国际合作"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "国际业务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "万泰生物：公司的鼻喷新冠疫苗已进入国际多中心的Ⅲ期临床试验阶段",
                "features": {
                    "keywords": [
                        "万泰生物",
                        "鼻喷新冠疫苗",
                        "Ⅲ期临床试验",
                        "国际多中心"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "疫苗研发"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}